With rapid advances in regenerative medicine, we are seeing numerous treatments for chronic conditions becoming possible realities. At the forefront of these breakthroughs are Canadian companies who are paving the way for this country to be a leader in emerging cell treatments for patients around the globe.
Using cell therapies can potentially improving outcomes in devastating diseases as diabetes, hemophilia, and critical limb ischemia, as well as conditions such as chronic tendinosis, damaged skin, and pattern baldness. Also the development of new tools and technologies are helping to eliminate intrusive methods to deliver life-saving treatments.
“We are at a powerful leading edge for medicine,” says Michael May, president and chief executive officer of the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto. “The ability to regenerate tissue will transform the treatment of diseases, quality of life, and the economics of health care.1”
“Billions are being spent globally in the field of regenerative medicine on investment, research, development and sales,” says May. “Now, with clinical efficacy being demonstrated, we’re seeing more regulatory approvals and resulting mega-deals between small companies and large corporations.1”
Canada is a natural leader in the cell therapy biotech industry. In the 1960s, stem cells were discovered in Canada and created a word-wide use for bone marrow transplant for leukemia and aplastic anemia patient. Now, Canada is in a position to be at the centre of this exciting and emerging industry.
To learn more about the Canadian companies that are revolutionizing cell therapies, please visit: https://business.financialpost.com/business-trends/canadas-emerging-cell-therapy-biotech-industry